Global Injectable Drug Delivery Market is expected to reach USD 1,104,096.5 million by 2025 from USD 378,998.2 million in 2017, at a CAGR of 12.4% in the forecast period 2018 to 2025. The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

To Get Free sample report @ - https://databridgemarketresearch.com/request-a-sample/?dbmr=global-injectable-drug-delivery-market-5

The global injectable drug delivery market is highly concentrated to a few big players and rest to local players who cater to domestic markets only.
• Baxter International, Inc.,
• Becton Dickinson and Company,
• Gerresheimer AG,
• Pfizer, Inc.,
• Schott AG,
• Alkermes Plc.,
• Eli Lilly
• and Company,
• Sandoz,
• Terumo Corporation,
• Teva Pharmaceuticals Industries Ltd.,
• Ypsomed,
• and Bespak, among other players

Market Segmentation: Global Injectable Drug Delivery Market
• The global injectable drug delivery market is segmented on of type, portability, type, product type, application, usage pattern, mode of administration, end user, distribution channel, and geography. The report provides data for 2016 to 2025, 2017 being the current year while 2018 to 2025 is the forecast period for the report.
• The global injectable drug delivery market is segmented based on type into two notable segments; injectable drug delivery device and injectable drug delivery formulation.
• . The injectable drug delivery formulation is segmented into conventional drug delivery formulation and novel drug delivery formulation. The Injectable drug delivery market is dominated by formulations with 75.7% market share in 2018, growing at a CAGR of 12.4% and will cross USD 837,873.64 million by 2025.
• On the basis of application, the market is segmented into autoimmune disease, hormonal disorders, orphan diseases, oncology and others.
• The Injectable drug delivery market is dominated by hormonal disorders with 50.1% market share in 2018, growing at a CAGR of 12.1% and will cross USD 540,977.35 million by 2025. However, oncology segment is expected to grow at the highest CAGR of 13.6% in the forecast period, and is expected to reach USD 265,145.17 million in 2025 from USD 82,915.00 million in 2017
BECTON, DICKINSON AND COMPANY
Founded in 1897 as Becton, Dickinson and Company and head quartered in New Jersey, U.S. is focused on developing, manufacturing and sales of medical supplies, devices, laboratory equipment and diagnostic products. The company operates through two business segments: BD Medical and BD Life Sciences.
The company’s operations span across North & South America, Europe, Australia, China, India, Japan, Korea, Taiwan and South East Asia. Some of its subsidiaries include Accuri Cytometers, Inc. (Delaware), BD Holding S. de R.L. de C.V. (Mexico), Becton Dickinson AcuteCare Holdings, Inc. (Delaware), Becton Dickinson Asia Limited (Hong Kong), Becton Dickinson Austria GmbH (Austria), CareFusion Corporation (Delaware, and U.K. Medical, Ltd. (U.K.) among others

Request For TOC- https://databridgemarketresearch.com/toc/?dbmr=global-injectable-drug-delivery-market-5

PFIZER:
Incorporated in June 1942 and headquartered in New York, U.S. Pfizer Inc., is engaged in discovering, developing and, manufacturing of healthcare products. Pfizer Inc., operates through two segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The Company’s IH segment concentrates on creating and commercializing immunizations and prescriptions that enhance patients’ lives, and in addition products for the end user health care.
The company has a strong geographic presence in more than 40 countries across
North America, Latin America, Europe, Eastern Europe, the Middle East, Africa, and Asia-Pacific, with manufacturing units in Europe, the Middle East and Africa, Asia-Pacific, Japan, Latin America, and the U.S. The subsidiaries of the company include Agouron Pharmaceuticals (U.S.), G.D. Searle & Company (U.S.), Innopharma (U.S.), Greenstone (U.S.), Parke-Davis (U.S.), and Pfizer (U.K.)

BAXTER INTERNATIONAL:
Founded in 1931 and headquartered in Illinois, U.S., Baxter International, Inc. manufactures medical devices, pharmaceuticals, and biotechnology products. The company operates through two business segments, namely, BioScience and Medical Products. The company provides a wide range of products for the treatment of hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.
Through the Medical Products segment, the company offers intravenous solutions, administration and nutrition sets, drug reconstitution systems, prefilled syringes (with and without needles) and vials, and infusion pumps and inhalation anesthetics. On the other hand, the BioScience business segment focuses on the treatment of hemophilia and other bleeding disorders by processing recombinant and plasma-based proteins.
The company has a strong geographic presence across the globe, spanning North America, Europe, the Middle East, Africa, Latin America, and Asia-Pacific. The company has three subsidiaries, namely, Gambro (U.S.), Baxter Healthcare Corporation (U.S.), and Baxter World Trade Corporation (U.S.).

Inquiry Before Buying- https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-injectable-drug-delivery-market-5

About Us:
Data bridge Market Research is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our client’s needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few
Contact Us:
Data Bridge Market Research
Toll Free: +1-888-387-2818
For Customized Reports and Discounts- [email protected]